Matrix Metalloproteinase-7 and Matrix Metalloproteinase-9 in Pediatric Multiple Sclerosis
Abstract Matrix metalloproteinases and their tissue inhibitors play a key role in the pathogenesis of adult-onset multiple sclerosis, and were suggested as biomarkers of response to interferon-β, an established treatment in multiple sclerosis. However, data regarding pediatric population are scarce....
Gespeichert in:
| Veröffentlicht in: | Pediatric neurology 2012-09, Vol.47 (3), p.171-176 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 176 |
|---|---|
| container_issue | 3 |
| container_start_page | 171 |
| container_title | Pediatric neurology |
| container_volume | 47 |
| creator | Ünsal, Ylmaz, MD Kvlcm, Gücüyener, MD Ayşegül, Atak, MD Arzu, Aral, MD Esra, Gürkaş, MD Ercan, Demir, MD Ayşe, Serdaroğlu, MD |
| description | Abstract Matrix metalloproteinases and their tissue inhibitors play a key role in the pathogenesis of adult-onset multiple sclerosis, and were suggested as biomarkers of response to interferon-β, an established treatment in multiple sclerosis. However, data regarding pediatric population are scarce. We determined serum levels of matrix metalloproteinase-7, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinase-1 in children, and evaluated effects of interferon-β therapy on these measures. Serum samples from 14 children with relapsing, remitting multiple sclerosis at baseline and at month 12, and from 15 controls, were collected. Interferon-β treatment was initiated in eight patients. Mean serum matrix metalloproteinase-9 levels and matrix metalloproteinase-9/tissue inhibitor of matrix metalloproteinase-1 ratio were higher in patients compared with controls, and were reduced significantly in treated patients at month 12, but did not change in untreated patients. Mean matrix metalloproteinase-7 levels were lower in patients compared with controls, and increased significantly in the treated group, but did not change significantly in the untreated group. In pediatric multiple sclerosis, a shift in matrix metalloproteinase-9/tissue inhibitor of matrix metalloproteinase-1 balance toward proteolytic activity is evident, and interferon-β therapy demonstrates a beneficial effect on this disturbed balance. |
| doi_str_mv | 10.1016/j.pediatrneurol.2012.05.027 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1038616591</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0887899412002652</els_id><sourcerecordid>1038616591</sourcerecordid><originalsourceid>FETCH-LOGICAL-c567t-5553699b2600ca062d48522d257cc5e0fdabc85d0187c9759fb73a80d97b59723</originalsourceid><addsrcrecordid>eNqNkluLFDEQhYMo7rj6F6RBBF-6raSnckEQlmW9wA4Kqw8-hXS6GjJmusekW9x_b4YZFQVhn_KQ79SpqlOMPePQcODy5bbZUx_cnEZa0hQbAVw0gA0IdY-tuFZtjRzhPluB1qrWxqzP2KOctwCARqwfsjMhtG6F5iv2ZVMKhR_VhmYX47RP00xhdJlqVbmxr_77baowVh-PjQRfbZY4h32k6sZHSlMO-TF7MLiY6cnpPWef31x9unxXX394-_7y4rr2KNVcI2IrjemEBPAOpOjXGoXoBSrvkWDoXec19lAG80ahGTrVOg29UR0aJdpz9uJYtzT3baE8213InmJ0I01LthxaLblEw--Ctmssu4GCvjqivgyTEw12n8LOpdsC2UMMdmv_isEeYrCAtsRQ1E9PRku3o_639tfeC_D8BLjsXRySG33IfzgpNBhsC3d15Khs8HugZLMPNPrinMjPtp_CHRt6_U8dH8MYivVXuqW8nZY0lpAst7lo7M3hcg6HwwWAkCjan-btwkk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1033452880</pqid></control><display><type>article</type><title>Matrix Metalloproteinase-7 and Matrix Metalloproteinase-9 in Pediatric Multiple Sclerosis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Ünsal, Ylmaz, MD ; Kvlcm, Gücüyener, MD ; Ayşegül, Atak, MD ; Arzu, Aral, MD ; Esra, Gürkaş, MD ; Ercan, Demir, MD ; Ayşe, Serdaroğlu, MD</creator><creatorcontrib>Ünsal, Ylmaz, MD ; Kvlcm, Gücüyener, MD ; Ayşegül, Atak, MD ; Arzu, Aral, MD ; Esra, Gürkaş, MD ; Ercan, Demir, MD ; Ayşe, Serdaroğlu, MD</creatorcontrib><description>Abstract Matrix metalloproteinases and their tissue inhibitors play a key role in the pathogenesis of adult-onset multiple sclerosis, and were suggested as biomarkers of response to interferon-β, an established treatment in multiple sclerosis. However, data regarding pediatric population are scarce. We determined serum levels of matrix metalloproteinase-7, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinase-1 in children, and evaluated effects of interferon-β therapy on these measures. Serum samples from 14 children with relapsing, remitting multiple sclerosis at baseline and at month 12, and from 15 controls, were collected. Interferon-β treatment was initiated in eight patients. Mean serum matrix metalloproteinase-9 levels and matrix metalloproteinase-9/tissue inhibitor of matrix metalloproteinase-1 ratio were higher in patients compared with controls, and were reduced significantly in treated patients at month 12, but did not change in untreated patients. Mean matrix metalloproteinase-7 levels were lower in patients compared with controls, and increased significantly in the treated group, but did not change significantly in the untreated group. In pediatric multiple sclerosis, a shift in matrix metalloproteinase-9/tissue inhibitor of matrix metalloproteinase-1 balance toward proteolytic activity is evident, and interferon-β therapy demonstrates a beneficial effect on this disturbed balance.</description><identifier>ISSN: 0887-8994</identifier><identifier>EISSN: 1873-5150</identifier><identifier>DOI: 10.1016/j.pediatrneurol.2012.05.027</identifier><identifier>PMID: 22883281</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adolescent ; Biological and medical sciences ; biomarkers ; Child ; Children ; Data processing ; Female ; Humans ; Immunologic Factors - therapeutic use ; Interferon-beta - therapeutic use ; Male ; Matrilysin ; Matrix metalloproteinase ; Matrix Metalloproteinase 7 - blood ; Matrix Metalloproteinase 9 - blood ; Medical sciences ; Multiple sclerosis ; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis ; Multiple Sclerosis, Relapsing-Remitting - blood ; Multiple Sclerosis, Relapsing-Remitting - enzymology ; Neurology ; Pediatrics ; Proteolysis ; Serum levels ; Tissue Inhibitor of Metalloproteinase-1 - blood ; Treatment Outcome</subject><ispartof>Pediatric neurology, 2012-09, Vol.47 (3), p.171-176</ispartof><rights>Elsevier Inc.</rights><rights>2012 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2012 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c567t-5553699b2600ca062d48522d257cc5e0fdabc85d0187c9759fb73a80d97b59723</citedby><cites>FETCH-LOGICAL-c567t-5553699b2600ca062d48522d257cc5e0fdabc85d0187c9759fb73a80d97b59723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0887899412002652$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26280953$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22883281$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ünsal, Ylmaz, MD</creatorcontrib><creatorcontrib>Kvlcm, Gücüyener, MD</creatorcontrib><creatorcontrib>Ayşegül, Atak, MD</creatorcontrib><creatorcontrib>Arzu, Aral, MD</creatorcontrib><creatorcontrib>Esra, Gürkaş, MD</creatorcontrib><creatorcontrib>Ercan, Demir, MD</creatorcontrib><creatorcontrib>Ayşe, Serdaroğlu, MD</creatorcontrib><title>Matrix Metalloproteinase-7 and Matrix Metalloproteinase-9 in Pediatric Multiple Sclerosis</title><title>Pediatric neurology</title><addtitle>Pediatr Neurol</addtitle><description>Abstract Matrix metalloproteinases and their tissue inhibitors play a key role in the pathogenesis of adult-onset multiple sclerosis, and were suggested as biomarkers of response to interferon-β, an established treatment in multiple sclerosis. However, data regarding pediatric population are scarce. We determined serum levels of matrix metalloproteinase-7, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinase-1 in children, and evaluated effects of interferon-β therapy on these measures. Serum samples from 14 children with relapsing, remitting multiple sclerosis at baseline and at month 12, and from 15 controls, were collected. Interferon-β treatment was initiated in eight patients. Mean serum matrix metalloproteinase-9 levels and matrix metalloproteinase-9/tissue inhibitor of matrix metalloproteinase-1 ratio were higher in patients compared with controls, and were reduced significantly in treated patients at month 12, but did not change in untreated patients. Mean matrix metalloproteinase-7 levels were lower in patients compared with controls, and increased significantly in the treated group, but did not change significantly in the untreated group. In pediatric multiple sclerosis, a shift in matrix metalloproteinase-9/tissue inhibitor of matrix metalloproteinase-1 balance toward proteolytic activity is evident, and interferon-β therapy demonstrates a beneficial effect on this disturbed balance.</description><subject>Adolescent</subject><subject>Biological and medical sciences</subject><subject>biomarkers</subject><subject>Child</subject><subject>Children</subject><subject>Data processing</subject><subject>Female</subject><subject>Humans</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Interferon-beta - therapeutic use</subject><subject>Male</subject><subject>Matrilysin</subject><subject>Matrix metalloproteinase</subject><subject>Matrix Metalloproteinase 7 - blood</subject><subject>Matrix Metalloproteinase 9 - blood</subject><subject>Medical sciences</subject><subject>Multiple sclerosis</subject><subject>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - blood</subject><subject>Multiple Sclerosis, Relapsing-Remitting - enzymology</subject><subject>Neurology</subject><subject>Pediatrics</subject><subject>Proteolysis</subject><subject>Serum levels</subject><subject>Tissue Inhibitor of Metalloproteinase-1 - blood</subject><subject>Treatment Outcome</subject><issn>0887-8994</issn><issn>1873-5150</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkluLFDEQhYMo7rj6F6RBBF-6raSnckEQlmW9wA4Kqw8-hXS6GjJmusekW9x_b4YZFQVhn_KQ79SpqlOMPePQcODy5bbZUx_cnEZa0hQbAVw0gA0IdY-tuFZtjRzhPluB1qrWxqzP2KOctwCARqwfsjMhtG6F5iv2ZVMKhR_VhmYX47RP00xhdJlqVbmxr_77baowVh-PjQRfbZY4h32k6sZHSlMO-TF7MLiY6cnpPWef31x9unxXX394-_7y4rr2KNVcI2IrjemEBPAOpOjXGoXoBSrvkWDoXec19lAG80ahGTrVOg29UR0aJdpz9uJYtzT3baE8213InmJ0I01LthxaLblEw--Ctmssu4GCvjqivgyTEw12n8LOpdsC2UMMdmv_isEeYrCAtsRQ1E9PRku3o_639tfeC_D8BLjsXRySG33IfzgpNBhsC3d15Khs8HugZLMPNPrinMjPtp_CHRt6_U8dH8MYivVXuqW8nZY0lpAst7lo7M3hcg6HwwWAkCjan-btwkk</recordid><startdate>20120901</startdate><enddate>20120901</enddate><creator>Ünsal, Ylmaz, MD</creator><creator>Kvlcm, Gücüyener, MD</creator><creator>Ayşegül, Atak, MD</creator><creator>Arzu, Aral, MD</creator><creator>Esra, Gürkaş, MD</creator><creator>Ercan, Demir, MD</creator><creator>Ayşe, Serdaroğlu, MD</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>20120901</creationdate><title>Matrix Metalloproteinase-7 and Matrix Metalloproteinase-9 in Pediatric Multiple Sclerosis</title><author>Ünsal, Ylmaz, MD ; Kvlcm, Gücüyener, MD ; Ayşegül, Atak, MD ; Arzu, Aral, MD ; Esra, Gürkaş, MD ; Ercan, Demir, MD ; Ayşe, Serdaroğlu, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c567t-5553699b2600ca062d48522d257cc5e0fdabc85d0187c9759fb73a80d97b59723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Biological and medical sciences</topic><topic>biomarkers</topic><topic>Child</topic><topic>Children</topic><topic>Data processing</topic><topic>Female</topic><topic>Humans</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Interferon-beta - therapeutic use</topic><topic>Male</topic><topic>Matrilysin</topic><topic>Matrix metalloproteinase</topic><topic>Matrix Metalloproteinase 7 - blood</topic><topic>Matrix Metalloproteinase 9 - blood</topic><topic>Medical sciences</topic><topic>Multiple sclerosis</topic><topic>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - blood</topic><topic>Multiple Sclerosis, Relapsing-Remitting - enzymology</topic><topic>Neurology</topic><topic>Pediatrics</topic><topic>Proteolysis</topic><topic>Serum levels</topic><topic>Tissue Inhibitor of Metalloproteinase-1 - blood</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ünsal, Ylmaz, MD</creatorcontrib><creatorcontrib>Kvlcm, Gücüyener, MD</creatorcontrib><creatorcontrib>Ayşegül, Atak, MD</creatorcontrib><creatorcontrib>Arzu, Aral, MD</creatorcontrib><creatorcontrib>Esra, Gürkaş, MD</creatorcontrib><creatorcontrib>Ercan, Demir, MD</creatorcontrib><creatorcontrib>Ayşe, Serdaroğlu, MD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>Pediatric neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ünsal, Ylmaz, MD</au><au>Kvlcm, Gücüyener, MD</au><au>Ayşegül, Atak, MD</au><au>Arzu, Aral, MD</au><au>Esra, Gürkaş, MD</au><au>Ercan, Demir, MD</au><au>Ayşe, Serdaroğlu, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Matrix Metalloproteinase-7 and Matrix Metalloproteinase-9 in Pediatric Multiple Sclerosis</atitle><jtitle>Pediatric neurology</jtitle><addtitle>Pediatr Neurol</addtitle><date>2012-09-01</date><risdate>2012</risdate><volume>47</volume><issue>3</issue><spage>171</spage><epage>176</epage><pages>171-176</pages><issn>0887-8994</issn><eissn>1873-5150</eissn><abstract>Abstract Matrix metalloproteinases and their tissue inhibitors play a key role in the pathogenesis of adult-onset multiple sclerosis, and were suggested as biomarkers of response to interferon-β, an established treatment in multiple sclerosis. However, data regarding pediatric population are scarce. We determined serum levels of matrix metalloproteinase-7, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinase-1 in children, and evaluated effects of interferon-β therapy on these measures. Serum samples from 14 children with relapsing, remitting multiple sclerosis at baseline and at month 12, and from 15 controls, were collected. Interferon-β treatment was initiated in eight patients. Mean serum matrix metalloproteinase-9 levels and matrix metalloproteinase-9/tissue inhibitor of matrix metalloproteinase-1 ratio were higher in patients compared with controls, and were reduced significantly in treated patients at month 12, but did not change in untreated patients. Mean matrix metalloproteinase-7 levels were lower in patients compared with controls, and increased significantly in the treated group, but did not change significantly in the untreated group. In pediatric multiple sclerosis, a shift in matrix metalloproteinase-9/tissue inhibitor of matrix metalloproteinase-1 balance toward proteolytic activity is evident, and interferon-β therapy demonstrates a beneficial effect on this disturbed balance.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>22883281</pmid><doi>10.1016/j.pediatrneurol.2012.05.027</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0887-8994 |
| ispartof | Pediatric neurology, 2012-09, Vol.47 (3), p.171-176 |
| issn | 0887-8994 1873-5150 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1038616591 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adolescent Biological and medical sciences biomarkers Child Children Data processing Female Humans Immunologic Factors - therapeutic use Interferon-beta - therapeutic use Male Matrilysin Matrix metalloproteinase Matrix Metalloproteinase 7 - blood Matrix Metalloproteinase 9 - blood Medical sciences Multiple sclerosis Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Multiple Sclerosis, Relapsing-Remitting - blood Multiple Sclerosis, Relapsing-Remitting - enzymology Neurology Pediatrics Proteolysis Serum levels Tissue Inhibitor of Metalloproteinase-1 - blood Treatment Outcome |
| title | Matrix Metalloproteinase-7 and Matrix Metalloproteinase-9 in Pediatric Multiple Sclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T01%3A01%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Matrix%20Metalloproteinase-7%20and%20Matrix%20Metalloproteinase-9%20in%20Pediatric%20Multiple%20Sclerosis&rft.jtitle=Pediatric%20neurology&rft.au=%C3%9Cnsal,%20Ylmaz,%20MD&rft.date=2012-09-01&rft.volume=47&rft.issue=3&rft.spage=171&rft.epage=176&rft.pages=171-176&rft.issn=0887-8994&rft.eissn=1873-5150&rft_id=info:doi/10.1016/j.pediatrneurol.2012.05.027&rft_dat=%3Cproquest_cross%3E1038616591%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1033452880&rft_id=info:pmid/22883281&rft_els_id=1_s2_0_S0887899412002652&rfr_iscdi=true |